408 related articles for article (PubMed ID: 24782859)
41. Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection
Duehr J; Lee S; Singh G; Foster GA; Krysztof D; Stramer SL; Bermúdez González MC; Menichetti E; Geretschläger R; Gabriel C; Simon V; Lim JK; Krammer F
mSphere; 2018; 3(1):. PubMed ID: 29435494
[TBL] [Abstract][Full Text] [Related]
42. Establishment of Murine Infection Models with Biological Clones of Dengue Viruses Derived from a Single Clinical Viral Isolate.
Zheng Z; Li M; Liu Z; Jin X; Sun J
Virol Sin; 2020 Oct; 35(5):626-636. PubMed ID: 32451883
[TBL] [Abstract][Full Text] [Related]
43. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
[TBL] [Abstract][Full Text] [Related]
44. Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.
Grifoni A; Angelo M; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Botten J; Boyson J; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148797
[TBL] [Abstract][Full Text] [Related]
45. Infection of Aedes albopictus Mosquito C6/36 Cells with the
Teramoto T; Huang X; Armbruster PA; Padmanabhan R
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092581
[TBL] [Abstract][Full Text] [Related]
46. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
[TBL] [Abstract][Full Text] [Related]
47. Protective and enhancing interactions among dengue viruses 1-4 and Zika virus.
Katzelnick LC; Bos S; Harris E
Curr Opin Virol; 2020 Aug; 43():59-70. PubMed ID: 32979816
[TBL] [Abstract][Full Text] [Related]
48. Dengue human infection models to advance dengue vaccine development.
Larsen CP; Whitehead SS; Durbin AP
Vaccine; 2015 Dec; 33(50):7075-82. PubMed ID: 26424605
[TBL] [Abstract][Full Text] [Related]
49. CD4
Rivino L; Lim MQ
Immunology; 2017 Feb; 150(2):146-154. PubMed ID: 27763656
[TBL] [Abstract][Full Text] [Related]
50. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.
Libraty DH; Acosta LP; Tallo V; Segubre-Mercado E; Bautista A; Potts JA; Jarman RG; Yoon IK; Gibbons RV; Brion JD; Capeding RZ
PLoS Med; 2009 Oct; 6(10):e1000171. PubMed ID: 19859541
[TBL] [Abstract][Full Text] [Related]
51. Influenza and dengue virus co-infection impairs monocyte recruitment to the lung, increases dengue virus titers, and exacerbates pneumonia.
Schmid MA; González KN; Shah S; Peña J; Mack M; Talarico LB; Polack FP; Harris E
Eur J Immunol; 2017 Mar; 47(3):527-539. PubMed ID: 27995614
[TBL] [Abstract][Full Text] [Related]
52. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.
Weiskopf D; Angelo MA; Sidney J; Peters B; Shresta S; Sette A
J Virol; 2014 Oct; 88(19):11383-94. PubMed ID: 25056881
[TBL] [Abstract][Full Text] [Related]
53. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
54. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
[TBL] [Abstract][Full Text] [Related]
55. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
[TBL] [Abstract][Full Text] [Related]
56. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.
Yamanaka A; Suzuki R; Konishi E
Vaccine; 2014 Jul; 32(34):4289-95. PubMed ID: 24950360
[TBL] [Abstract][Full Text] [Related]
58. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
59. Identifying protective dengue vaccines: guide to mastering an empirical process.
Halstead SB
Vaccine; 2013 Sep; 31(41):4501-7. PubMed ID: 23896423
[TBL] [Abstract][Full Text] [Related]
60. Immune response to dengue virus and prospects for a vaccine.
Murphy BR; Whitehead SS
Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
